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Amiodarone and cardiac surgery
To the Editor:
The recent publication of a large random-
ized trial of amiodarone arrhythmia pro-
phylaxis after cardiac surgery (PAPA-
BEAR) is of great interest.1 It was striking
how similar the results of this trial were to
our previous observational analysis of peri-
operative amiodarone during mitral valve
repair,2 and a detailed comparison raises
several points. First, both studies con-
cluded that amiodarone was effective, re-
ducing postoperative atrial arrhythmias by
half and virtually eliminating mortality
from ventricular arrhythmias. Second, seri-
ous complications of a brief perioperative
administration were rare. In PAPABEAR,
bradycardia requiring dose reduction oc-
curred in 5.7% of cases and was considered
a side effect. In clinical practice, however,
postoperative bradycardia can be managed
easily with transient atrial pacing, and re-
duction to a low discharge dose is routine.
Third, only low-risk patients undergoing
elective procedures were randomly as-
signed in PAPABEAR, which limited
event rates and statistical power to define
other clinical benefits, similar to the AFIST
trial.3 The use of large national databases
for such studies could allow better sample
sizes and would certainly be less costly.
The patients most likely to achieve abso-
lute event reductions are those at the very
highest risk (ie, those most prone to non-
fatal and fatal arrhythmias). Those patients
often undergo operation on an emergency
basis and thus are not candidates for a
prolonged preoperative oral protocol.
In the acute setting, 12 hours of stan-
dard intravenous loading (150-mg intra-
venous bolus followed by 1-mg/min in-
travenous infusion for 6 hours and then
0.5-mg/min intravenous infusion) per-
forms well,2 similar to the “hybrid” pro-
tocol of AFIST II.4 The infusion is con-
tinued postoperatively, and additional
150-mg bolus doses are administered ag-
gressively for persistent sinus tachycar-
dia or the appearance of arrhythmias.
Dose reductions are prompted by (1) ob-
served lengthening of the P-R or Q-T
interval or (2) reduction in the underlying
sinus rate to 70 to 80 beats/min. Oral
amiodarone is begun on the first postop-
erative day at 400 mg orally every 6
hours, and the intravenous agent is over-
lapped for 24 hours. Then, the oral dose
is progressively reduced to 200 mg orally
twice daily at discharge, again guided by
optimizing the sinus rate to 70 to 80
beats/min. If the sinus rate is especially
sensitive to the drug, the discharge dose
can be reduced all the way to 100 mg
orally daily. The discharge dose is con-
tinued orally for 3 to 4 weeks after sur-
gery to prevent the occasional “late
breakthrough” and then stopped abruptly,
because amiodarone has a prolonged ef-
fect after discontinuation. If sinus tachy-
cardia is difficult to control, very low
doses of -blockers can be added with
synergistic effect.
After using this approach for more
than 10 years,2 it is now routine for all
cardiac procedures, with a clinical expe-
rience that parallels PAPABEAR. Abso-
lute benefits, however, are even more im-
pressive in high-risk patients. Aggressive
and routine arrhythmia prophylaxis with
this safer and more effective agent has
been a major advance in the care of car-
diac surgical patients. This approach
could significantly reduce the current rate
of postoperative arrhythmias, which have
occurred in as many as a third of cardiac
patients in recent series.5
J. Scott Rankin, MD
Centennial Medical Center
Vanderbilt University
Nashville, Tenn
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